Project Updates

Spark Therapeutics

Credit; Commonwealth of Pennsylvania. 

Location: Philadelphia, USA 
Project type: Gene Therapy Innovation Center 
Expected Completion: 2026 
Estimated Investment: Phase 1: $575m

Spark Therapeutics, a US-based biotechnology company and a member of the Roche Group, began construction of a new Gene Therapy Innovation Center on Drexel University’s campus. The facility will serve as Roche’s global centre of excellence for gene therapy manufacturing.

Boehringer Ingelheim

Credit; Boehringer Ingelheim

Location: Biberach, Germany 
Project type: Research and development facility 
Construction Started: June 2018 
Completed: April 2023

Boehringer Ingelheim developed a biologicals development centre and invested €350m ($384.6m) in the state-of-the-art facility. It is Europe’s largest development centre in biotechnology. The facility is used for conducting advanced research for cancer, stroke and heart disease and other conditions.

Cellares

Credit; Cellares Corporation

Location: Bridgewater, New Jersey, US 
Project type: Cell therapy development facility 
Estimated Investment: $255m 
Expected Completion: 2024

Cellares, a US-based Integrated Development and Manufacturing Organization (IDMO) focused on cell therapy, will launch its first IDMO Smart Factory in Bridgewater, New Jersey, US, for pre-clinical, clinical and commercial-scale cell therapy manufacturing.

Go to article: Home | How pharma wants to break the efficacy ceiling in IBDGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: UrsatecGo to article: SHL Medical Company InsightGo to article: SHL MedicalGo to article: ControlantGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: Owen Mumford Company InsightGo to article: Owen MumfordGo to article:  Sensified.ioGo to article: In DepthGo to article: How pharma wants to break the efficacy ceiling in IBDGo to article: Subcutaneous drugs grant a new lease on life to checkpoint inhibitorsGo to article: Hope for the UK clinical trial landscape but it requires a lot of work Go to article: Novo Nordisk’s Wegovy to start being supplied by NHS in EnglandGo to article: Minimal impact expected for first ten drugs released for Medicare price negotiationGo to article: Q&A: Human touch remains critical for the patient experience in trialsGo to article: Zenatek Company InsightGo to article: BEA TechnologiesGo to article: ListingsGo to article: EventsGo to article: AwardsGo to article: Buyer's GuidesGo to article: Next issue